Confronted with budget constraints on one hand and expanding health care costs on the other hand, healthcare payers and providers are increasingly demanding health economic evaluations in order to allocate their budgets to medical interventions with the highest health gain per invested euro. High standard guidelines are continuously developed to ensure the objectivity and quality of health economic studies, increasing the investments required for health economic studies. Moreover, an increasing demand for post-marketing observational studies emerges to justify reimbursement and pricing decisions.
Well-prepared companies aiming to optimize their market access, product uptake and reimbursement, need to include health economics and outcomes research in their product development strategy quite early in the product life cycle. Timely and well-designed health economic studies throughout the entire product lifecycle will ensure an optimal market access and reimbursement at an optimal use of resources and investments..